about
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep LossEfficacy Study of Lisdexamfetamine to Treat Bipolar DepressionEfficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue SyndromeEffectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With SchizophreniaAttention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation StudyEfficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)The Effects of Vyvanse(TM) on Brain Hemodynamics and ReadingPharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery PatientsEffectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity DisorderPilot Study of Lisdexamfetamine for Treatment of Cocaine DependenceEffects of LDX on Functioning of College Students With ADHDLisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy VolunteersSPD489 as Adjunctive Treatment in Adults With Negative Symptoms of SchizophreniaBariatric Surgery and Pharmacokinetics of LisdexamphetamineEfficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHDOpen-Label Pilot Study of Lisdexamfetamine for Cocaine DependenceCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance TreatmentForced-dose Titration of SPD489 in Adults With Binge Eating DisorderSafety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II DisorderLisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to MethylphenidateDoes Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance?Open Label Extension in Adults With Binge Eating Disorder (BED)Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple SclerosisSafety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaSPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of SchizophreniaCognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute TreatmentClinical Efficacy of Lisdexamfetamine for Methamphetamine DependenceEvaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating DisorderLDX for the Treatment of Cognitive Functioning Issues in Women Post-OophorectomyE2 and LDX for the Treatment of Cognitive Complaints After OophorectomyLDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal WomenAn fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHDNeurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain ActivationSequencing Treatments for Mothers With ADHD and Their At - Risk ChildrenAdjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
P4844
Q61936531-C371B06F-BEE9-481C-8F6F-F0574111FB27Q61936830-5D862E46-F2AE-4AE7-9E5C-81A0F5F15A78Q61938731-5B27C947-8EDB-4BB7-8265-C04293C1BB9EQ61938812-93881163-E437-4C7F-8CF9-E129B06A9946Q61965977-71106DCC-2C90-43C5-8C7B-92E3BBE3086AQ63063342-7851F892-635A-4D8B-8DB1-167F2235652EQ63063460-2AF36C18-0564-4BA1-B577-35F3954FDF3AQ63063712-DA0D85C6-7375-4148-AB0B-F256B883CA4CQ63229096-202A53A5-1A8A-4EBD-8792-BC2EDFAEB027Q63319394-6B8676DB-422E-447E-BC33-08C767A986F6Q63320884-BCB112C3-A7BE-4EB3-A9A0-26884DCC105BQ63337556-1CB0716F-3E16-4BCF-90B2-664C62CB8BB2Q63338450-DF85DEFE-068C-4760-9C4B-7907F6CF5BB8Q63340756-1A036C37-0172-4AD7-969C-3C486EA408F4Q63340845-8D94EE8B-1FBF-4C7B-9423-0DC7E94DB210Q63399958-FBE65C7B-082C-4F5D-858E-16EA3E769147Q63401664-62B7C5E4-35BF-4116-8EC1-FCDF73FFB876Q63572747-43ECDFA7-8C4E-475D-84DE-4660FF330DB6Q63587015-9E7C0ED3-1569-4E67-AC75-D9454D812C9AQ63814110-8AB21934-13BF-4C49-8539-FF8DDF33D51BQ63815383-6A6C3C22-96BC-4BB0-B6AA-B88A8DDC70B5Q63817038-BC31C836-6191-47CE-9FAB-9ACE61BBA83EQ63830112-CC06122A-7DDD-4993-BA60-2D4D73316906Q63834279-8FBFBC2F-925F-4072-9DBE-EA17CF0552B8Q63837129-8FCD3C64-DAFD-4D47-BA25-E52071BF3492Q63841001-4B7A5DDE-1E8C-4431-853E-F44A5E4AC239Q63842850-A00AE1C2-7185-4511-9A6A-489AC0A60942Q64043485-B74ED49D-0B0B-461F-83A3-4ADCE0E5CB1AQ64070455-93D7FC0F-56EA-4F32-BE3E-3D661C9B4DDDQ64070482-27EE8C14-4ED1-480D-B1C8-41634182B226Q64189619-B149E311-CA00-4699-8534-127DEF89C1CFQ64349069-F9DD4238-04EE-4ABD-A0BE-FED446DFB2D2Q64351253-FDA53900-E997-4F15-907F-5790ABEC2AD2Q64352014-D8925F25-B8B4-45E8-89B8-88068E158916Q64352016-912348A0-227F-43E4-B015-F0D1B9240364Q64352797-397A0DF1-F3A7-4256-8754-D72976D12B5FQ64606567-7306B7F2-5AD1-4649-8A92-DB34996CC56FQ64621780-C062C684-55F6-4502-98DA-85B3B8D0CDA3Q64625642-D7B6BD88-277D-45C6-B88F-75CA1DE36D75Q64636398-E4AF594A-B118-4B5F-8D57-AF2ED2D987F5
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
lisdexamfetamine dimesylate
@en
type
label
lisdexamfetamine dimesylate
@en
prefLabel
lisdexamfetamine dimesylate
@en
P486
P592
P661
P662
P2017
C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
P2067
P2115
N0000176090
P231
608137-33-3
P233
CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N.CS(=O)(=O)O.CS(=O)(=O)O
P234
1S/C15H25N3O.2CH4O3S/c1-12(11- ...... 3,(H,2,3,4)/t12-,14-;;/m0../s1
P235
CETWSOHVEGTIBR-FORAGAHYSA-N
P274
C₁₇H₃₃N₃O₇S₂
P2892
P3117
DTXSID60209653
P3345
P486
D000069478
P592
CHEMBL1201178
P652
SJT761GEGS